|
|
 Previous Article | Table of Contents | Next Article 
Monitoring of minimal residual disease by quantitative reverse
transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2
with t(8; 21)
K Tobal and JA Yin
University Department of Haematology, Manchester Royal Infirmary, UK.
We have developed a quantitative reverse transcriptase-polymerase chain
reaction method for the quantitation of AML1-MTG8 transcripts in patients
with AML-M2 and t(8;21) in different phases of the disease. Using this
method, we have tested sequential samples from 13 patients to monitor
minimal residual disease and were able to show a significant increase in
AML1-MTG8 transcripts level in two patients 2 and 4 months before clinical
relapse. In five patients tested at presentation and then sequentially at
remission, we detected a marked decrease in the level of AML1-MTG8
transcripts as the treatment progressed. Patients in long-term remission of
their disease had a level of up to 1 x 10(3) AML1-MTG8 molecules/microgram
RNA. Two patients tested 2 and 4 months before hematologic relapse showed a
level of 0.71 x 10(5) molecules/microgram RNA and this level increased
further during relapse to 0.71 x 10(7) and 2.27 x 10(5) molecules/microgram
RNA, respectively. Our results show that quantitation of AML1-MTG8
transcripts by competitive polymerase chain reaction is valuable in
predicting early relapse in AML with t(8;21). Identification of at-risk
patients may allow treatment to be modified to include additional or
alternative therapy such as bone marrow transplantation.
Volume 88,
Issue 10,
pp. 3704-3709,
11/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. R. Sperr, M. Mitterbauer, G. Mitterbauer, M. Kundi, U. Jager, K. Lechner, and P. Valent
Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse
Clin. Cancer Res.,
September 15, 2005;
11(18):
6536 - 6543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Kottaridis, R. E. Gale, S. E. Langabeer, M. E. Frew, D. T. Bowen, and D. C. Linch
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
Blood,
September 18, 2002;
100(7):
2393 - 2398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Sperr, J.-H. Jordan, M. Baghestanian, H.-P. Kiener, P. Samorapoompichit, H. Semper, A. Hauswirth, G.-H. Schernthaner, A. Chott, S. Natter, et al.
Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia
Blood,
October 1, 2001;
98(7):
2200 - 2209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Rhoades, C. J. Hetherington, N. Harakawa, D. A. Yergeau, L. Zhou, L.-Q. Liu, M.-T. Little, D. G. Tenen, and D.-E. Zhang
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
Blood,
September 15, 2000;
96(6):
2108 - 2115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tobal, J. Newton, M. Macheta, J. Chang, G. Morgenstern, P. A. S. Evans, G. Morgan, G. S. Lucas, and J. A. L. Yin
Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
Blood,
February 1, 2000;
95(3):
815 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Hosler, R. O. Bash, X. Bai, V. Jain, and R. H. Scheuermann
Development and Validation of a Quantitative Polymerase Chain Reaction Assay to Evaluate Minimal Residual Disease for T-Cell Acute Lymphoblastic Leukemia and Follicular Lymphoma
Am. J. Pathol.,
April 1, 1999;
154(4):
1023 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, Z. Estrov, U. Machida, M. Kami, H. Hirai, H. Cave, S. Suciu, and E. Vilmer
Detection of Residual Disease in Childhood Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
January 14, 1999;
340(2):
152 - 154.
[Full Text]
|
|
|
|
|
|
|
N.C. Gorin
Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia
Blood,
August 15, 1998;
92(4):
1073 - 1090.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hunger, M. Z. Fall, B. M. Camitta, A. J. Carroll, M. P. Link, S. J. Lauer, D. H. Mahoney, D. Jeanette Pullen, J. J. Shuster, C. Philip Steuber, et al.
E2A-PBX1 Chimeric Transcript Status at End of Consolidation Is Not Predictive of Treatment Outcome in Childhood Acute Lymphoblastic Leukemias With a t(1;19)(q23;p13): A Pediatric Oncology Group Study
Blood,
February 1, 1998;
91(3):
1021 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Elmaagacli, D. W. Beelen, J. Stockova, S. Trzensky, M. Kroll, U. W. Schaefer, C. Stein, B. Opalka;, J. Jurlander, M. A. Caligiuri, et al.
Detection of AML1/ETO Fusion Transcripts in Patients With t(8; 21) Acute Myeloid Leukemia After Allogeneic Bone Marrow Transplantation or Peripheral Blood Progenitor Cell Transplantation
Blood,
October 15, 1997;
90(8):
3230 - 3231.
[Full Text]
[PDF]
|
|
|
|
|
